SECTORS TODAY
Tech XLK -4.89%
Financials XLF -0.76%
Healthcare XLV +0.45%
Energy XLE +1.91%
Industrials XLI -1.60%
Cons. Disc. XLY -0.71%
Cons. Staples XLP +1.41%
Utilities XLU +0.67%
Materials XLB +0.40%
Real Estate XLRE +0.26%
Comm. Svcs XLC -1.29%

Earnings release · VTRS

Viatris Reports Second-Quarter 2026 Financial Results

Viatris Inc · Filed · SEC Form 8-K, Item 2.02

Viatris Inc company page Original on SEC.gov ↗

Revenue — +3.5% vs a year ago
EPS (adjusted) $0.69 +11% vs a year ago
Guidance raisedoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete. Please read the original before relying on any figure. Not investment advice.

Why it matters

Revenue rose 3.5% year on year, and EPS grew 11% to $0.69. Growth in both sales and earnings is the combination investors usually look for first. Management raised its outlook, and guidance changes often matter more to the market than the quarter just reported because they reflect expectations for the periods ahead.

Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.

What the company states

Revenue

n/a +3.5% vs a year ago

…Total Revenues Were Up 3.5% Operationally Compared to Second Quarter 2025…
EPS (adjusted)

$0.69 +11% vs a year ago

…al basis compared to the second quarter of 2025, and adjusted EPS was $0.69 per share, up 11% on a reported basis and up 9% on an operational bas…
Guidance

Guidance raised

…Raises 2026 Financial Guidance Midpoints for All Metrics [1]. | Our strong first-half results give us the confidence to raise our full-year guidance.…

Read the original press release on SEC.gov ↗ Filing index ↗

Trend: last 1 reports

All releases →

Revenue growth (YoY)

EPS growth (YoY)

Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.

Get new research in your inbox

Forensic equity research on US stocks. No spam, unsubscribe anytime.